extent of aggregation and an enhancement of granular ATP secretion. Concentrations of rapamycin in the ng Background. Rapamycin is a new immunosuppressive drug of the macrolide type. Despite binding to one of range, as well as short pre-incubation times (within min), were sufficient to cause significant enhancement the FK-binding proteins as the initial step in intracellular action, further effects differ from those of the other of agonist-induced platelet aggregation and secretion (P<0.001) as compared with their vehicle controls. fungally derived macrolides, cyclosporine and tacrolimus. We have previously demonstrated an enhance-Conclusions. Rapamycin significantly potentiates agonist-induced platelet aggregation in a time-and ment of agonist-mediated platelet activation by cyclosporine and tacrolimus which was associated with dose-dependent manner. As these findings are similar to those observed with the other fungal macrolides, we increased phosphorylation of two intracellular platelet proteins, p20 and p40. Because rapamycin utilizes the hypothesize that inhibition of calcineurin may not be necessary for the increase in intracellular protein phossame class of binding proteins as tacrolimus, but its action is not associated with the inhibition of cal-phorylation observed following exposure of platelets to cyclosporine or tacrolimus. Whether the rapamycincineurin, we postulated that if the stimulatory effect of cyclosporine or tacrolimus was due to calcineurin induced enhancement of sensitivity to agonists and platelet hyperaggregability explains the thrombocytopinhibition, rapamycin should not affect platelets in a similar fashion.
lent, TRAP-6, were measured as changes in optical Introduction transmission in a Chronolog lumi-aggregometer. Each experiment was repeated at three or more times and Atherosclerosis has become the leading cause of death the mean results were used for statistical comparison.
in long-term (>10 years) transplant survivors and Results. Rapamycin-treated platelets demonstrated an progresses at an accelerated rate [1] . Chronic, lowincrease in their dose-and time-dependent sensitivity grade platelet activation may play a role in the generato ADP, resulting in a significantly enhanced primary tion of atherosclerosis and potentially in the genesis of wave of ADP-induced platelet aggregation followed chronic rejection, which remains the leading cause of by a secondary wave of aggregation, indicative of renal allograft loss [2] . Platelets become activated by granule secretion. Furthermore, rapamycin-treated a number of physiological agonists including ADP, platelets showed significantly enhanced sensitivity to epinephrine, thrombin, collagen, platelet-activating TRAP-6 as demonstrated by an increase in the initial factor and stimulatory antibodies directed against velocity of aggregation, an increase in their maximal specific platelet membrane proteins [3] . Once activated, platelets synthesize thromboxane A 2 , which has been
Correspondence and offprint requests to: Mariana S. Markell, MD, (PDGF ) and TGF-b, agents which have been implictaining NaCl (137 mM ), KCl (2.7 mM ), MgCl 2 (1 mM ), ated in the genesis of progressive renal diseases [4] . observed on renal biopsy, which resembles the haemolytic-uremic syndrome [7] . This entity has also been noted in patients treated with tacrolimus (FK 506) Platelet aggregation, ATP secretion and preparation of [11] , as has an increase in thrombotic episodes, primar-rapamycin ily deep venous thromboses [12] .
The platelet aggregation experiments were carried-out at
Our previous studies have shown that both CSA 37°C under stirring conditions in a Chronolog lumiand tacrolimus significantly enhance platelet aggregaaggregometer (Chronolog Corp., Havertown, PA).
tion and secretion in response to physiological agonists Aggregation tracings were plotted on a dual channel recorder [13, 14] . The agonist-stimulated response of platelets is as a change in optical transmission following the addition of greater following tacrolimus exposure than following the platelet agonist ADP which was purchased from exposure to CSA, which parallels the drugs' immuno-Chronolog Corp. or the thrombin receptor agonist peptide, suppressant potencies [12] .
a calcineurin-independent mechanism and might Quantitations of the maximal extent of ADP-or TRAPexplain the dose-dependent fall in platelet counts which induced platelet aggregation were determined by measuring has been observed in patients when the drug is used light transmission units (LTU ) displayed on a chart recorder. clinically [15] .
The initial velocity of platelet aggregation was measured from the initial slope of the platelet aggregation tracing and expressed as LTU/min. In parallel, ATP secretion was measured by adding the luciferin/luciferase reagent (Chronolog
Materials and methods
Corp.) during platelet aggregation.
Preparation and washing of platelets Statistical analysis
Whole blood was collected by venipuncture from healthy donors as described previously in accordance with protection Statistical analysis was performed by the SUNY Scientific of human subjects as per the Institutional Review Board [3] . and Academic Computing Center, Brooklyn, NY, using Donors were drug-free for at least 2 weeks prior to blood SPSS for Windows Release 6.1. and by use of Sigma Stat. donation. Blood (7 vol ) was collected in the anticoagulant acid-citrate-dextrose (1 vol ) and was mixed gently at 22°C.
Platelet-rich plasma (PRP) was obtained from blood by Results centrifugation 200 g for 10 min at 22°C. The inhibitors PGE 1 (1 mM ), apyrase (1 unit/ml ) and heparin (2 units/ml ) were A representative example of the response of washed added to the PRP. The washed platelets were pelleted by platelets to the agonist ADP (in the absence of rapamycentrifugation at 1100 g for 10 min. The platelets were washed as described previously [3] . In brief, the platelet pellet was cin) is shown in Figure 1A . The initial slope of the Fig. 2 . Dose-response relationship of ADP-induced platelet aggregation in the presence of various concentrations of rapamycin. Washed human platelets (450 ml; 2-4×108/ml ) were incubated with the final concentrations of rapamycin (100 ng, 220 ng, 2.2 mg, 7.3 mg, 11.1 mg and 22.2 mg per ml ) (or with an identical volume of the DMSO vehicle) for 1 min at 37°C under stirring conditions. Aliquots (10 ml ) of the agonist, ADP (11 mM ), were added to initiate platelet aggregation and the extents of aggregation [measured in light transmission units (LTU )] were determined for all samples treated alone. The extent of platelet aggregation in the absence of rapamycin to the agonist ADP (arrow) (11 mM, final concentration) in the was set at 100%. One sample t-tests were used to compare the extent presence of the control vehicle. (B) Enhanced response of washed of platelet aggregation at each dose of rapamycin relative to its human platelets to ADP (11 mM, final concentration) in the presence control for three experiments. A P-value of <0.05 was considered of rapamycin (1 mg/ml ) depicting the induction of both a primary significant. The asterisk (*) indicates significant differences between and secondary wave of aggregation associated with secretion. This treated and untreated samples. At a rapamycin concentration of figure is representative of three or more separate experiments. 0.22 mg/ml, the P-value was very close to significant, P=0.053. In addition, a Bonferroni correction was performed for small group size. The values obtained at 2. extent of ADP-induced platelet aggregation (LTU ) from which the maximal extent of aggregation is determined. Figure 1B shows the response of platelets that rapamycin exerts its procoagulant effects in vitro by interacting directly with platelets, and does not pre-incubated for 1 min with rapamycin, to the addition of the agonist ADP. On the one hand, as shown require the presence of additional plasma factors.
The dose-response relationship of the effect of rapain these experiments, the addition of ADP, in the presence of the vehicle control solution ( Figure 1A) , mycin in the induction of agonist-induced platelet hyperaggregability, following a 1 min pre-incubation resulted in a very low degree of platelet aggregation, which was observed to be monophasic and reversible. period, is shown in Figure 2 . The data points represent the mean±standard error (SEM ) for ADP-induced On the other hand, pre-incubation of platelet suspensions with rapamycin ( Figure 1B ) resulted in a signi-platelet aggregations tested at various concentrations of rapamycin. Concentrations of rapamycin of 100 ng, ficant robust increase (600%) in the initial velocity of platelet aggregation and a significant increase in the 220 ng and 2.2 mg/ml produced an increase in platelet aggregation in response to ADP ranging from 150 to extent of platelet aggregation in response to identical concentrations of ADP. As demonstrated in Figure 300% over control values. Concentrations of rapamycin of 100 ng and 2.2 mg/ml produced a significant 1B, we consistently observed a transition from a low monophasic reversible response in the absence of rapa-(P<0.05) increase in platelet hyperaggregability, and treatment of platelets with a concentration of mycin, to an enhanced response to ADP (shown here by the biphasic response in the presence of rapamycin) 220 ng/ml also resulted in an approximate 200% increase in platelet hyperaggregability in response to consisting of a primary wave of aggregation followed by a secondary wave of aggregation representing active ADP with a P-value very close to significant (P<0.053). Approximately 50% of maximal hyperaginduction of granular secretion. Such enhancement of platelet aggregation (termed hyperaggregability) by gregability was achieved at a rapamycin concentration of 220 ng/ml, and a rapamycin concentration of rapamycin resulted in an irreversible platelet aggregation. As these experiments were conducted with washed 2.2 mg/ml resulted in approximately 86% of maximal hyperaggregability. A plateau in hyperaggregability platelets free of additional plasma proteins (other than exogenously added fibrinogen), our results indicate was achieved at concentrations of rapamycin between Washed human platelets were incubated in the presence of rapamycin or in the presence of an identical volume of vehicle for 30 min at (1 mg) or in the presence of vehicle control for 1, 10 or 30 min at 37°C followed by the addition of ADP (11 mM ) to initiate platelet 37°C under stirring conditions. ADP (11 mM ) was added to initiate aggregation. The effect of aggregation in the absence of rapamycin platelet aggregation. The values are depicted as the percent of was set at 100%. One sample t-tests were used to compare each dose platelet aggregation in the presence of rapamycin, as compared with of rapamycin relative to its control. A Bonferroni correction was control ADP-induced aggregations (set at 100%) were significant used to control for the number of comparisons. A P-value of different. One sample t-tests were used to compare each dose of <0.0125 was considered significant. The asterisk (*) indicates signirapamycin relative to its control. A P-value of <0.05 was considered ficant difference (P<0.01) between the treated and control groups.
significant. At 100 ng rapamycin, the P-value was 0.016. Values are the mean±SEM for three or more experiments.
in TRAP-induced platelet aggregation which was associated, in parallel, with a potent induction of granular 7.3 and 11.1 mg/ml. The highest concentration of rapamycin examined, 22.2 mg/ml, also resulted in a signific-secretion as measured by the release of dense-granulecontaining ATP ( lower panel of Figure 5A ). In the ant increase in the extent of ADP-induced platelet aggregation.
absence of rapamycin ( Figure 5B ), only a small, reversible platelet aggregation was evident in response to Figure 3 represents a dose-response curve of rapamycin-induced platelet hyperaggregability (at concen-TRAP, and no ATP secretion could be detected ( lower panel of Figure 5B ). The dose-response relationship trations of 25-200 ng/ml ), as might be encountered at peak plasma levels clinically. After a 30-min pre-of rapamycin-induced platelet sensitivity was examined by using the extent of platelet aggregation as a measure incubation with rapamycin, we observed an enhancement of ADP-stimulated platelet aggregation at all of platelet hyperaggregability. Figure 6 demonstrates that incubation of platelets with rapamycin at a conconcentrations of rapamycin examined, with significant differences observed at concentrations of 50 ng/ml centration of 430 ng/ml produced a significant (P<0.001) enhancement (of approximately 300%) in (P<0.006) and 200 ng/ml (P<0.001); significance at 100 ng/ml was not observed owing to the large variance the extent of TRAP-induced platelet aggregation. The enhancement of platelet aggregation at this concentrain the results at this concentration.
The effect of pre-incubation time on rapamycin-tion of rapamycin was approximately 43% of the maximal level, and approximately 80% of the maximal induced platelet hyperaggregability is shown in Figure  4 . One concentration of rapamycin was selected response was observed at a concentration of 1.1 mg/ml.
Lower concentrations of rapamycin of 110 and (1 mg/ml ), and the pre-incubation time with rapamycin was examined. We observed that a short incubation of 220 ng/ml did not reveal significant differences between control vehicle-treated samples and rapamycin-treated 1 min with rapamycin resulted in a 150% increase in the extent of ADP-induced platelet aggregation. At samples, however a tendency for an increase in the extent of platelet aggregation could be observed at longer periods of incubation with rapamycin (10 and 30 min), rapamycin treatment caused further increases these lower concentrations of rapamycin. Maximal hyperaggregability induced by rapamycin was observed in the extent of ADP-induced platelet aggregation.
Since ADP provides information concerning only at a concentration of 2.2 mg/ml and resulted in a significant enhancement in the extent of platelet one pathway of platelet activation, the agonist TRAP (a thrombin equivalent, termed the thrombin receptor aggregation, of up to 10-to 14-fold ( Figure 6 ).
Rapamycin also increased the TRAP-induced initial agonist peptide) was examined for its effects on platelet function in the presence of rapamycin. Figure 5A velocity of platelet aggregation as shown in Figure 7 .
Concentrations of rapamycin in the ng range significshows the potentiating role of rapamycin when TRAP is used as the agonist. Incubation of platelets with antly increased (by 2-fold ) the initial velocity of platelet aggregation induced by TRAP, whereas mg concentrarapamycin (2 min at 37°C ) resulted in a 600% increase tions of rapamycin further enhanced (5-7-fold over destruction of platelets, or whether such a decrease resulted from a direct effect on the suppression of controls) the initial velocity of platelet aggregation resulting in the observed platelet hyperaggregability megakaryopoiesis. These clinical studies [15] were performed using cyclosporine and rapamycin concomitand enhanced ATP secretion.
antly, and cyclosporine has been demonstrated to have an independent effect responsible for the enhancement
Discussion
of platelet aggregation [8] [9] [10] . Therefore, future studies will require the evaluation of the effects of cyclosporine and rapamycin together in vitro, in order to determine Our data strongly suggest that rapamycin is a potent whether these compounds produce profound synerenhancer of platelet aggregation and secretion at congistic effects on platelet activation. centrations which may occur at peak plasma levels,
The present study suggests that significant alterations and that this effect does not require the presence of in platelet function can occur following rapamycin plasma proteins, but is a direct effect of rapamycin on exposure in a pattern which resembles that observed platelet function. Pre-incubation times as short as following pre-incubation with other fungally derived 1 min resulted in increased platelet aggregation and immunosuppressants, cyclosporine or tacrolimus secretion, thus, the exposure of platelets to transient [13, 14] . Although rapamycin binds to a class of FKrises in rapamycin levels, which occur following human binding proteins, the FK-BP-rapamycin complex does ingestion of the compound, could have profound clinnot inhibit calcineurin [17] suggesting that the inhibiical effects.
tion of calcineurin is not the mechanism by which the Preclinical data have demonstrated a dose-dependent enhanced intracellular protein phosphorylation and association of rapamycin administration with desubsequent platelet activation occur following exposure creased platelet count [15] . Presently it is not known of platelets to cyclosporine. whether such decreases in platelet count occurred due Low-grade platelet activation has been implicated in to enhanced platelet clumping and aggregation in vivo, whether the decrease in platelet count was due to the many long-term effects, including atherogenesis and chronic rejection [1, 2] , and does not always manifest as thrombotic events. Platelets are important sources of PDGF and TGF-b, substances which have been implicated in progressive fibrotic diseases of the kidney [4] . It is conceivable that following endothelial injury during acute rejection, pre-sensitized platelets may undergo low-grade activation, leading to the release of metabolically active substances such as PDGF and TGF-b, followed by progressive fibrosis, the hallmark of chronic rejection, over time.
Further studies are needed to elucidate the biochemical processes underlying the effects of immunosuppressant agents on platelet function, in order to understand the effects of these drugs on cells other than in those of the immune system, and to enable the design of therapeutic regimens which will minimize the toxicity of these compounds. Fig. 6 . Enhancement of the extent of thrombin receptor agonist ( TRAP)-induced platelet aggregation by rapamycin. Washed human platelets (450 ml; 2-4×108/ml ) were incubated in the presence of Acknowledgements. We acknowledge the excellent statistical intervarious concentrations of rapamycin (as shown above) for 1 min at pretation of the data which was provided by Dr Peter Homel of the 37°C under stirring conditions. Control samples were incubated with Scientific and Academic Computing Center at SUNY Health Science the vehicle in an identical manner. Aliquots (6 ml ) of the agonist, Center at Brooklyn, NY. TRAP (1 mg/ml, final concentration), were added to initiate platelet aggregation. The extents of aggregation measured in light transmission units (LTU ) were determined for all samples treated with
